-SEC Filing
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2021 | $22.00 | Buy | Maxim Group |
| 12/20/2021 | $18.00 | Buy | HC Wainwright & Co. |
| 11/30/2021 | $12.00 → $17.00 | Hold → Buy | Jefferies |
| 8/17/2021 | $27.00 → $25.00 | Outperform | Oppenheimer |
| 7/13/2021 | $29.00 | Buy | Ladenburg Thalmann |
Maxim Group initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $22.00
HC Wainwright & Co. initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $18.00
Jefferies upgraded Ayala Pharmaceuticals from Hold to Buy and set a new price target of $17.00 from $12.00 previously
3 - Old Ayala, Inc (0001797336) (Issuer)
3 - Old Ayala, Inc (0001797336) (Issuer)
3 - Old Ayala, Inc (0001797336) (Issuer)
SC 13G/A - Old Ayala, Inc (0001797336) (Subject)
SC 13G - Old Ayala, Inc (0001797336) (Subject)
SC 13G/A - Old Ayala, Inc (0001797336) (Subject)
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX:ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the na
REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place in-person November 16-19 in Vancouver, Canada. The ongoing RINGSIDE Pivotal Phase 2/3 clinical trial is evaluating the investigational new drug AL102, a poten
REHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI). "We are pleased to begin enrollment in the Phase 3 segment of RINGSIDE, which is a significant milestone in our AL102 development program," said Roni Mamluk, Ph.D., President and Chief Exec
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggress
10-K - Old Ayala, Inc (0001797336) (Filer)
15-12G - Old Ayala, Inc (0001797336) (Filer)
8-K - Old Ayala, Inc (0001797336) (Filer)
Gainers Hepion Pharmaceuticals (NASDAQ:HEPA) stock increased by 72.2% to $0.79 during Tuesday's after-market session. At the close, Hepion Pharmaceuticals's trading volume reached 954.9K shares. This is 348.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $60.3 million. Tivic Health Systems (NASDAQ:TIVC) shares rose 16.89% to $0.64. The company's market cap stands at $6.1 million. Lixte Biotech Hldgs (NASDAQ:LIXT) shares increased by 10.28% to $0.59. The company's market cap stands at $9.8 million. Nutex Health (NASDAQ:NUTX) stock moved upwards by 8.04% to $1.88. The company's market cap stands at $1.2 billion. Alzamend Neuro (NASDAQ:AL
-SEC Filing
On Tuesday, 31 stocks hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Apple (NASDAQ:AAPL). Tuesday Morning (NASDAQ:TUEM) was the smallest firm by market cap to set a new 52-week low. Biora Therapeutics (NASDAQ:BIOR)'s stock dropped the most, trading down 2329.76% to reach a new 52-week low. Tuesday Morning (NASDAQ:TUEM) shares were the most resilient of the group, as shares actually moved up 0.0% in response to hitting its 52-week low. The following stocks created new 52-week lows on Tuesday: Apple (NASDAQ:AAPL) shares set a new 52-week low of $125.23. The stock traded down 3.12%. Rivian Autom